Clinical trial
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
NCT00233675 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00233675 |
|---|---|
| Title | Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder |
| Official title | A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | General Anxiety Disorder |
| Intervention type | Drug |
| Interventions | GABITRIL (tiagabine hydrochloride, CEP-6671) |
| Start date | Aug 1, 2003 |
| Primary completion | Feb 1, 2005 |
| First posted | Oct 6, 2005 |
| Last update posted | Apr 12, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: